In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Skin Protectant Final Rule Allows Cross-Monograph Ingredient Combinations

This article was originally published in The Rose Sheet

Executive Summary

The Skin Protectant Final Monograph covering products for minor cuts, scrapes, burns, chapped skin and lips, poison ivy, poison oak, poison sumac and insect bites allows for certain cross-monograph ingredient combinations, according to the rule published in the 1Federal Register June 4

Related Content

FDA Clarifies Skin Protectant Labeling, Ingredient Combination Options
FDA guides industry in labeling skin protectants
Skin protectant monograph
FDA In Brief
FDA Proposed Rule To Ban Use Of Cervids Exposed To CWD In Cosmetics
Playtex In Vitro Sunscreen Test Predicts In Vivo UVA Protection, Firm Says
UK Sunscreen Labeling Should Employ SPF System For UVA – Research Group
Skin Protectant Reduced Labeling For All Lip Products Urged By Mentholatum
Skin Protectant Chafing Indications Should Be Included In Final Rule - CTFA
Astringent Final Rule Contains Revised Labeling, Small Package Exemptions



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts